Virtus ETF Advisers’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Virtus ETF Advisers’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,893	Closed	-$105K	–	497
2022 Q1	$105K	Sell	3,893 -238	-6%	-$8K	0.05%	294
2021 Q4	$197K	Buy	4,131 +1,396	+51%	+$62.4K	0.07%	215
2021 Q3	$182K	Sell	2,735 -145	-5%	-$10.3K	0.08%	295
2021 Q2	$225K	Buy	2,880 +514	+22%	+$38K	0.09%	261
2021 Q1	$224K	Buy	2,366 +33	+1%	+$3.92K	0.09%	310
2020 Q4	$284K	Sell	2,333 -2,701	-54%	-$296K	0.12%	240
2020 Q3	$440K	Sell	5,034 -694	-12%	-$48.3K	0.23%	152
2020 Q2	$370K	Sell	5,728 -770	-12%	-$44.4K	0.18%	238
2020 Q1	$290K	Sell	6,498 -946	-13%	-$50.2K	0.12%	226
2019 Q4	$464K	Buy	+7,444	New	+$354K	0.08%	212

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Virtus ETF Advisers's TPTX Position: Q2 2022 in Review

Virtus ETF Advisers sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 3,893 shares — an estimated $105K sold.

Virtus ETF Advisers first reported a position in TPTX in Q4 2019 and held it in 10 quarters. The position peaked at $464K in Q4 2019. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

Virtus ETF Advisers reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Virtus ETF Advisers sold 3,893 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $105K.
Virtus ETF Advisers first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 10 quarters.
Virtus ETF Advisers's Turning Point Therapeutics, Inc. Common Stock position peaked at $464K in Q4 2019.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.